AbbVie Shares Outstanding 2010-2024 | ABBV
AbbVie shares outstanding history from 2010 to 2024. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
- AbbVie shares outstanding for the quarter ending September 30, 2024 were 1.772B, a 0.06% increase year-over-year.
- AbbVie 2023 shares outstanding were 1.773B, a 0.28% decline from 2022.
- AbbVie 2022 shares outstanding were 1.778B, a 0.06% increase from 2021.
- AbbVie 2021 shares outstanding were 1.777B, a 6.22% increase from 2020.
AbbVie Annual Shares Outstanding
(Millions of Shares) |
| 2023 |
1,773 |
| 2022 |
1,778 |
| 2021 |
1,777 |
| 2020 |
1,673 |
| 2019 |
1,484 |
| 2018 |
1,546 |
| 2017 |
1,603 |
| 2016 |
1,631 |
| 2015 |
1,637 |
| 2014 |
1,610 |
| 2013 |
1,604 |
| 2012 |
1,577 |
| 2011 |
1,577 |
| 2010 |
1,577 |
| 2009 |
|
AbbVie Quarterly Shares Outstanding
(Millions of Shares) |
| 2024-09-30 |
1,772 |
| 2024-06-30 |
1,771 |
| 2024-03-31 |
1,773 |
| 2023-12-31 |
1,773 |
| 2023-09-30 |
1,771 |
| 2023-06-30 |
1,771 |
| 2023-03-31 |
1,776 |
| 2022-12-31 |
1,778 |
| 2022-09-30 |
1,776 |
| 2022-06-30 |
1,776 |
| 2022-03-31 |
1,778 |
| 2021-12-31 |
1,777 |
| 2021-09-30 |
1,777 |
| 2021-06-30 |
1,776 |
| 2021-03-31 |
1,775 |
| 2020-12-31 |
1,673 |
| 2020-09-30 |
1,774 |
| 2020-06-30 |
1,647 |
| 2020-03-31 |
1,484 |
| 2019-12-31 |
1,484 |
| 2019-09-30 |
1,483 |
| 2019-06-30 |
1,484 |
| 2019-03-31 |
1,483 |
| 2018-12-31 |
1,546 |
| 2018-09-30 |
1,515 |
| 2018-06-30 |
1,572 |
| 2018-03-31 |
1,596 |
| 2017-12-31 |
1,603 |
| 2017-09-30 |
1,603 |
| 2017-06-30 |
1,600 |
| 2017-03-31 |
1,603 |
| 2016-12-31 |
1,631 |
| 2016-09-30 |
1,640 |
| 2016-06-30 |
1,632 |
| 2016-03-31 |
1,625 |
| 2015-12-31 |
1,637 |
| 2015-09-30 |
1,664 |
| 2015-06-30 |
1,633 |
| 2015-03-31 |
1,608 |
| 2014-12-31 |
1,610 |
| 2014-09-30 |
1,610 |
| 2014-06-30 |
1,608 |
| 2014-03-31 |
1,609 |
| 2013-12-31 |
1,604 |
| 2013-09-30 |
1,605 |
| 2013-06-30 |
1,609 |
| 2013-03-31 |
1,605 |
| 2012-12-31 |
1,577 |
| 2012-09-30 |
1,577 |
| 2012-06-30 |
1,577 |
| 2012-03-31 |
1,577 |
| 2011-12-31 |
1,585 |
| 2011-09-30 |
1,300 |
| 2011-06-30 |
1,571 |
| 2011-03-31 |
|
| 2010-12-31 |
|
| 2009-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$354.099B |
$54.318B |
|
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
|
